Phase II Clinical Study of E7389 for Advanced or Relapsed Breast Cancer.

Trial Profile

Phase II Clinical Study of E7389 for Advanced or Relapsed Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2013

At a glance

  • Drugs Eribulin (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 19 Aug 2013 Start and end dates of the extension trial amended as reported by ClinicalTrials.gov. Changed from Aug 2009 - Nov 2010 to Jan 2008 - Jan 2011.
    • 19 Aug 2013 Start and end dates of the extension trial amended as reported by ClinicalTrials.gov. Changed from Aug 2009 - Nov 2010 to Jan 2008 - Jan 2011.
    • 11 Oct 2011 Actual end date of the extension trial (NCT00965523) is Nov 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top